IPL Pharma Services Limited 10628382 false 2025-04-01 2026-03-31 2026-03-31 The principal activity of the company is consultancy in industrial pharmaceuticals Digita Accounts Production Advanced 6.30.9574.0 true 10628382 2025-04-01 2026-03-31 10628382 2026-03-31 10628382 bus:OrdinaryShareClass1 2026-03-31 10628382 bus:OrdinaryShareClass2 2026-03-31 10628382 bus:OrdinaryShareClass3 2026-03-31 10628382 bus:OrdinaryShareClass4 2026-03-31 10628382 core:RetainedEarningsAccumulatedLosses 2026-03-31 10628382 core:ShareCapital 2026-03-31 10628382 core:CurrentFinancialInstruments 2026-03-31 10628382 core:CurrentFinancialInstruments core:WithinOneYear 2026-03-31 10628382 core:FurnitureFittingsToolsEquipment 2026-03-31 10628382 bus:SmallEntities 2025-04-01 2026-03-31 10628382 bus:AuditExemptWithAccountantsReport 2025-04-01 2026-03-31 10628382 bus:FilletedAccounts 2025-04-01 2026-03-31 10628382 bus:SmallCompaniesRegimeForAccounts 2025-04-01 2026-03-31 10628382 bus:RegisteredOffice 2025-04-01 2026-03-31 10628382 bus:Director1 2025-04-01 2026-03-31 10628382 bus:OrdinaryShareClass1 2025-04-01 2026-03-31 10628382 bus:OrdinaryShareClass2 2025-04-01 2026-03-31 10628382 bus:OrdinaryShareClass3 2025-04-01 2026-03-31 10628382 bus:OrdinaryShareClass4 2025-04-01 2026-03-31 10628382 bus:PrivateLimitedCompanyLtd 2025-04-01 2026-03-31 10628382 core:FurnitureFittingsToolsEquipment 2025-04-01 2026-03-31 10628382 core:OfficeEquipment 2025-04-01 2026-03-31 10628382 countries:EnglandWales 2025-04-01 2026-03-31 10628382 2025-03-31 10628382 core:FurnitureFittingsToolsEquipment 2025-03-31 10628382 2024-04-01 2025-03-31 10628382 2025-03-31 10628382 bus:OrdinaryShareClass1 2025-03-31 10628382 bus:OrdinaryShareClass2 2025-03-31 10628382 bus:OrdinaryShareClass3 2025-03-31 10628382 bus:OrdinaryShareClass4 2025-03-31 10628382 core:RetainedEarningsAccumulatedLosses 2025-03-31 10628382 core:ShareCapital 2025-03-31 10628382 core:CurrentFinancialInstruments 2025-03-31 10628382 core:CurrentFinancialInstruments core:WithinOneYear 2025-03-31 10628382 core:FurnitureFittingsToolsEquipment 2025-03-31 iso4217:GBP xbrli:pure xbrli:shares

Registration number: 10628382

IPL Pharma Services Limited

Unaudited Financial Statements

for the Year Ended 31 March 2026

 

IPL Pharma Services Limited

(Registration number: 10628382)
Balance Sheet as at 31 March 2026

Note

2026
£

2025
£

Fixed assets

 

Tangible assets

4

2,482

3,272

Current assets

 

Debtors

5

31,057

28,685

Cash at bank and in hand

 

190,808

181,915

 

221,865

210,600

Creditors: Amounts falling due within one year

6

(45,990)

(49,596)

Net current assets

 

175,875

161,004

Net assets

 

178,357

164,276

Capital and reserves

 

Called up share capital

7

100

100

Retained earnings

178,257

164,176

Shareholders' funds

 

178,357

164,276

For the financial year ending 31 March 2026 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476.

The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006 and FRS 102 Section 1A.

Approved and authorised by the director on 31 July 2026
 

.........................................
Dr I P Leader
Director

   
 

IPL Pharma Services Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2026

1

General information

The company is a private company limited by share capital, incorporated in England and Wales.

The address of its registered office is: c/o Barrett & Co, 15 Dukes Ride, Crowthorne, Berkshire, RG45 6LZ.

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A - 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006.

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of value added tax, returns, rebates and discounts. The company recognises revenue when the amount of revenue can be reliably measured, it is probable that future economic benefits will flow to the entity and specific criteria have been met for each of the company's activities.

Tax

The tax expense for the period comprises current tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

Tangible assets

Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses. The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class

Depreciation method and rate

Office equipment

25% straight line

 

IPL Pharma Services Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2026

2

Accounting policies (continued)

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business. Debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the debtor.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Creditors are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities. Creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Share capital

Ordinary shares are classified as equity. All shares are issued on a fully paid up basis.

Dividends

Dividend distribution to the company’s shareholders is recognised as a liability in the financial statements in the reporting period in which the dividends are declared.

Defined contribution pension obligation

A defined contribution plan is a pension plan under which fixed contributions are paid into a pension fund and the company has no legal or constructive obligation to pay further contributions even if the fund does not hold sufficient assets to pay all employees the benefits relating to employee service in the current and prior periods.

Contributions to defined contribution plans are recognised as employee benefit expense when they are due. If contribution payments exceed the contribution due for service, the excess is recognised as a prepayment.

3

Staff numbers

The average number of persons employed by the company (including the director) during the year, was 3 (2025 - 4).

 

IPL Pharma Services Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2026

4

Tangible assets

Furniture, fittings and equipment
 £

Total
£

Cost or valuation

At 1 April 2025

14,251

14,251

Additions

1,166

1,166

Disposals

(958)

(958)

At 31 March 2026

14,459

14,459

Depreciation

At 1 April 2025

10,979

10,979

Charge for the year

1,956

1,956

Eliminated on disposal

(958)

(958)

At 31 March 2026

11,977

11,977

Carrying amount

At 31 March 2026

2,482

2,482

At 31 March 2025

3,272

3,272

5

Debtors

Current

2026
£

2025
£

Trade debtors

29,967

25,671

Prepayments

1,090

1,210

Other debtors

-

1,804

 

31,057

28,685

 

IPL Pharma Services Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2026

6

Creditors

Creditors: amounts falling due within one year

2026
£

2025
£

Taxes and social security

44,389

47,941

Directors current accounts

149

-

Other creditors

1,452

1,655

45,990

49,596

7

Share capital

Allotted, called up and fully paid shares

2026

2025

No.

£

No.

£

A Ordinary Shares of £1 each

55

55

55

55

B Ordinary Shares of £1 each

25

25

25

25

C Ordinary Shares of £1 each

10

10

10

10

D Ordinary Shares of £1 each

10

10

10

10

100

100

100

100